Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards

Recruiting Phase 4 Interventional Study
Hypomagnesemia
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 90
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
330 (estimated)
Sponsor
Frieda Wolf · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Hypomagnesemia is a common entity in the inpatient and outpatient setting. in previous retrospective study hypomagnesemic patients have higher mortality and longer hospitalization. whether hypomagnesemia is merely a marker of poor prognosis, or whether replacing it can improve outcomes is unclear. The current standard of care is to discharge these patients without workup or further treatment, even…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Any patient admitted over the age of 18, has hypomagnesemia (magnesium level ≤1.9 mg/dL) and is able to give consent. Exclusion Criteria: * A patient unable to give consent. * A patient admitted for an elective procedure. * A patient in critical condition or dying. * Patient…
Contacts

Frieda Wolf

972-4-6495476

friedawo@clalit.org.il

CONTACT

Rotem Shvartzman

972-4-6495351

rotem_sw@clait.org.il

CONTACT